Biopharma looks to single-cell RNA-seq for biomarker discovery, to identify targets that can personalize therapy and increase efficacy.
Most scRNA-seq technologies require complex equipment that is too expensive for sample collection sites, forcing biopharma to rely on cryopreservation to ship samples to advanced research labs across the globe. Cryopreservation damages fragile and sparse cells, biasing samples — what you freeze is not what you thaw.
This application note from Revvity discusses how the Hive scRNA-seq Solution can enable scRNA-seq studies with global sample collection and centralized lab processing for use in biomarker and target discovery.
Offered Free by: Revvity Health Sciences
See All Resources from: Revvity Health Sciences